ABAD vincula directamente a Abeta con la toxicidad mitocondrial en la enfermedad de Alzheimer
Video Experimental Relacionado
Updated: Jul 24, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Joyce W Lustbader1, Maurizio Cirilli, Chang Lin
1Center for Reproductive Sciences and Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA.
Science (New York, N.Y.)
|April 17, 2004
Resumen
La alcohol deshidrogenasa (ABAD) vincula directamente el beta-amiloide (Abeta) con la toxicidad mitocondrial en la enfermedad de Alzheimer (EA). La inhibición de esta interacción protege las neuronas y mejora la memoria en modelos de ratón.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Biología Molecular Biología Molecular
- La bioquímica es la bioquímica.
Sus antecedentes:
- La disfunción mitocondrial es una característica clave del daño neuronal en la enfermedad de Alzheimer (EA), a menudo desencadenada por los péptidos beta-amiloide (Abeta).
- Los mecanismos moleculares precisos que conectan a Abeta con la toxicidad mitocondrial no se comprenden completamente.
Objetivo del estudio:
- Para investigar el papel de la alcohol deshidrogenasa (ABAD) como un enlace molecular entre Abeta y la disfunción mitocondrial en la enfermedad de Alzheimer.
- Explorar el potencial de dirigir la interacción Abeta-ABAD como una estrategia terapéutica para la enfermedad de Alzheimer.
Principales métodos:
- Examinó la interacción entre Abeta y ABAD en mitocondrias de pacientes con EA y ratones transgénicos.
- Determinó la estructura cristalina de ABAD unido a Abeta para comprender su efecto sobre la actividad enzimática.
- Utilizó un péptido ABAD específico para inhibir la interacción Abeta-ABAD en cultivos neuronales y modelos de ratón.
Principales resultados:
- Abeta interactúa directamente con ABAD dentro de las mitocondrias de los cerebros de AD.
- La estructura cristalina reveló que la unión de Abeta deforma el sitio activo de ABAD, lo que impide la unión de nicotinamida adenina dinucleótido (NAD).
- La inhibición de la interacción Abeta-ABAD por un péptido redujo la apoptosis neuronal inducida por Abeta y la generación de radicales libres.
- Los ratones transgénicos que sobreexpresaban ABAD mostraron un aumento del estrés oxidativo neuronal y déficits de memoria en un entorno rico en Abeta.
Conclusiones:
- La interacción entre Abeta y ABAD sirve como un vínculo molecular directo a la toxicidad mitocondrial en la enfermedad de Alzheimer.
- Dirigirse a la interacción Abeta-ABAD presenta una vía terapéutica prometedora para mitigar la neurotoxicidad inducida por Abeta y el deterioro cognitivo en la enfermedad de Alzheimer.
Más Videos Relacionados
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
06:27Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
Published on: November 30, 2018
Videos de Conceptos Relacionados
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...